Latest Oncology News

Sotorasib Flips the Switch for Patients With KRAS G12C-Mutant NSCLC

August 2nd 2021

Jackie Collins

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Hayley Virgil

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021

Courtney Marabella

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021

Hayley Virgil

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

KRAS Inhibitors Reach New Milestones in NSCLC

July 31st 2021

Caroline Seymour

Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

Latest Oncology Videos

DLBCL: Approaches to Treating Patients Ineligible for Transplant

Steroid-Refractory Chronic GVHD

Dr. Reckamp on the Significance of ALTA in ALK+ NSCLC

Capmatinib for MET Exon 14-Mutated NSCLC

Concluding Remarks in Lung Cancer Screening Following COVID-19

Data From the L-MIND Trial

Emerging Agents and Biomarkers in Gastric and GEJ Cancers

Sequencing After Progression on IO-Based Therapy for mGC

Frontline Therapy for Metastatic PD-L1–, HER2+ Gastric Cancer

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

Dr. Arcila on Choosing Between Molecular Tests in Lung Cancer

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

Frontline Therapy for Patients With CLL: Testing and Risk Classification

Use of PSMA PET Scans in Advanced Prostate Cancer

Testing for PSMA in Community Settings

Impact of Targeted Therapy in CLL

Steroid-Refractory Acute GVHD

PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer

Dr. Willmott on Using Genetic Testing to Inform PARP Inhibitor Selection in Ovarian Cancer

Dr. Abida on the Clinical Significance of the TRITON2 Study in mCRPC

Dr. Masrouha on the Challenges of Surgical Removal of Chordoma Tumors

All Oncology News

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

July 31st 2021

Kristi Rosa

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Ryan Scott

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

CDK4/6 Inhibitors Continue to Build Traction in Early-Stage ER+/HER2- Breast Cancer

July 30th 2021

Caroline Seymour

Neoadjuvant and adjuvant treatment with CDK4/6 inhibitors has shown encouraging preliminary evidence in patients with estrogen receptor–positive, HER2-negative breast cancer, but confirmation of durable benefit is needed in the adjuvant setting before they are brought into routine clinical practice.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021

Gina Mauro

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

July 30th 2021

Brittany Lovely

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

Kyle Doherty

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

FDA Grants Fast Track Status to Eryaspase for Hypersensitive Acute Lymphocytic Leukemia

July 30th 2021

Kristi Rosa

The FDA has granted a fast track designation to eryaspase for use as a potential therapeutic option in patients with acute lymphocytic leukemia who have developed hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

Zanubrutinib Significantly Prolongs PFS Over Chemoimmunotherapy in Treatment-Naïve CLL

July 30th 2021

Kristi Rosa

Zanubrutinib resulted in a significant improvement in progression-free survival per independent review committee assessment vs bendamustine plus rituximab in treatment-naïve patients with chronic lymphocytic leukemia whose tumors did not exhibit the deletion of chromosome 17p13.1.

Adjuvant Nivolumab Approved in Europe for Select Esophageal or GEJ Cancers

July 30th 2021

Kristi Rosa

The European Commission has approved nivolumab for use as an adjuvant treatment in adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after neoadjuvant chemoradiation.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

July 29th 2021

Caroline Seymour

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021

Jessica Hergert

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Dr. Thompson on Treatment Considerations With BTK Inhibitors in CLL

July 29th 2021

Meghan Thompson, MD

Meghan Thompson, MD, discusses treatment considerations with BTK inhibitors in chronic lymphocytic leukemia.

Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers

July 29th 2021

OncLive Staff

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up

July 29th 2021

Brittany Lovely

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

Identification of Patients for Germline Testing

July 29th 2021

Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center

The panel of experts provide insight on how they identify patients for germline testing.

See All News